Comparison
Cagrilintide vs. Octreotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
1415456-99-3
83150-76-9
Molecular weight
4253.7 g/mol
1019.24 g/mol
Half-life
168 h
1.7 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYD-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2